U-M spin-off CytoPherx grows to 12 people

Wednesday, April 7, 2010 | Source: Concentrate
Kidney disease is one of those things you don't want to be diagnosed with. The disease has a survival rate that peaks at 30 percent and goes down quickly. University of Michigan spin-off CytoPherx hopes its new technology will reverse those numbers.

The Ann Arbor-based firm is developing new therapies for patients who suffer from acute and chronic kidney disease. It hopes to flip the current survival rates so 70 percent or more of patients with kidney disease can go onto to live fulfilling lives.

"So far the early indicators suggest we can do it," says Mark Morsfield, CFO of CytoPherx.

The nearly 3-year-old start-up employs 12 people, a couple of independent contractors and the occasional intern. The company started with three people. It is in the midst of putting its therapies through clinical trials. That process promises to bump up the staff to 18 people within the next two years as it heads toward its expected commercialization.

Source: Mark Morsfield, CFO of CytoPherx
Writer: Jon Zemke
Enjoy this story? Sign up for free solutions-based reporting in your inbox each week.

Related Tags

Entrepreneurship, Healthcare, Higher Education, Medical Research, University Of Michigan 

Recommended Content

Related Company

Sponsored By
Regions
Focus Areas
Copyright © Issue Media Group. All rights reserved.